Welcome to CDC stacks |
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
Clear All Simple Search
Advanced Search
Large-scale geographic seroprevalence surveys
  • Published Date:
    July 21, 2020
  • Language:
Filetype[PDF-85.99 KB]

  • Description:
    Updated July 21, 2020

    Large-scale Geographic Seroprevalence Survey Samples

    Commercial Laboratory Survey

    Blood Donor Survey

    CDC wants to learn more about the percentage of people in the United States who have been infected with SARS-CoV-2, the virus that causes COVID-19 and to better understand how the virus is spreading through the U.S. population over time. Because infected people can have mild illness or may not get medical care or testing, CDC also wants to use this information to estimate the number of people who have been previously infected with SARS-CoV-2 and were not included in official case counts. To help answer those questions and others, CDC is collaborating with public health and private partners on a variety of seroprevalence surveys of different sizes, locations, populations studied, and purposes.

    Seroprevalence surveys use serology tests to identify people in a population or community that have antibodies against an infectious disease. Antibodies are specific proteins made in response to infections. Antibodies are detected in the blood of people who are tested after infection; they show an immune response to the infection. Antibody test results are especially important for detecting previous infections in people who had few or no symptoms. It is not known yet if having antibodies to the virus that causes COVID-19 can protect someone from getting infected again, or, if they do, how long this protection might last. CDC and its partners plan to study this issue.

    CDC is conducting seroprevalence surveys called “large-scale geographic seroprevalence surveys” in locations across the United States. The first seroprevalence surveys began in areas that first reported community transmission of SARS-CoV-2 in the United States; they are now being expanded to more regions. Descriptions of these surveys are provided below.

  • Content Notes:
    Commercial Laboratory Survey -- Blood Donor Survey -- CDC Seroprevalence Survey Types.
  • Document Type:
  • Main Document Checksum:
No Related Documents.
You May Also Like: